Medial Patellofemoral Ligament Reconstruction for Knee Dislocation
(SHYFT Trial)
Trial Summary
What is the purpose of this trial?
The aim of this study is to investigate the role of tibial tubercle osteotomy (TTO) on the subjective and objective outcomes following medial patellofemoral ligament reconstruction (MPFL-R) in patients with an increased tibial tubercle-trochlear groove (TT-TG) distance with or without patella alta. This Pilot RCT will assess the feasibility of conducting this study for: 1. The ability to recruit study patients 2. Adherence to the study protocol 3. Completion rates of patient follow-up at a minimum of 12 months post-operative
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Medial patellofemoral ligament reconstruction for knee dislocation?
Research shows that medial patellofemoral ligament (MPFL) reconstruction is commonly used to treat recurrent patellar dislocation, which is when the kneecap frequently slips out of place. Although there are reports of complications and failures, it remains a popular choice for addressing patellofemoral instability, especially in younger patients.12345
Is medial patellofemoral ligament reconstruction generally safe for humans?
How is medial patellofemoral ligament reconstruction different from other treatments for knee dislocation?
Medial patellofemoral ligament reconstruction is a unique surgical technique specifically designed to address recurrent patellar instability and dislocation by reconstructing the ligament that helps stabilize the kneecap. Unlike other treatments, it focuses on restoring the natural anatomy and biomechanics of the knee, which can be particularly beneficial for patients with repeated dislocations.12359
Research Team
Laurie A Hiemstra, MD, PhD
Principal Investigator
University of Calgary
Eligibility Criteria
This trial is for young people aged 13-30 with recurrent knee cap dislocation and specific bone alignment issues (TT-TG ≥15mm on MRI or ≥18mm on CT). They must have mature bones, confirmed by x-rays. It's not for those with certain knee ratios, excessive femoral or tibial rotation, severe groove deformities needing surgery, advanced arthritis in the kneecap joint, cartilage restoration procedures, inability to do computer questionnaires or if pregnant.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo either isolated MPFL-R or MPFL-R with TTO surgery
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 6, 12, and 24 months post-operative
Long-term Follow-up
Participants continue to be monitored for long-term outcomes and complications
Treatment Details
Interventions
- Medial patellofemoral ligament reconstruction
Medial patellofemoral ligament reconstruction is already approved in European Union, United States, Canada for the following indications:
- Patellar instability
- Recurrent patellar dislocation
- Patellar instability
- Recurrent patellar dislocation
- Patellar instability
- Recurrent patellar dislocation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Banff Sport Medicine Foundation
Lead Sponsor
ConMed Corporation
Industry Sponsor
CONMED Corporation
Industry Sponsor
Canadian Orthopaedic Foundation
Collaborator